AzTrials
AzTrials

FentanylNCT07836595

Fentanyl Vs Dexmedetomidine as Adjuvants to Bupivacaine in Erector Spinae Plane Block for Postoperative Analgesia in Patients Undergoing Arthroscopic Shoulder Surgeries

A study testing Bupivacaine 0.25%, Bupivacaine 0.25% + Fentanyl 1µg/kg and Bupivacaine 0.25% + dexmedetomidine 1µg/kg in people with Fentanyl and Dexmedetomidine, run by Tanta University at 1 site in Egypt.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record

Search all trials

Trial summary

This study aimed to evaluate the effect of fentanyl versus dexmedetomidine as adjuvants to bupivacaine with comparison to bupivacaine alone in ultrasound-guided erector spinae plane block on the quality and duration of pain control in patients undergoing arthroscopic shoulder surgeries. Read more about this study

Who is it for?
Ages 21 to 60 years
Conditions the study is for
Fentanyl, Dexmedetomidine, Bupivacaine
What is being tested?
Bupivacaine 0.25%, Bupivacaine 0.25% + Fentanyl 1µg/kg and Bupivacaine 0.25% + dexmedetomidine 1µg/kg
Could I receive a placebo?
No, everyone receives an active treatment
How many people
90 participants
Where
1 siteEgypt
Study dates
1 Jan 2024to 1 Dec 2024
Phase
Interventional

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 21 to 60 years
  • All sexes
  • No healthy volunteers
  • Adult

Who may be able to join

  • Both sexes.
  • Age from 21 to 60 years.
  • Belonging to American Society of Anesthesiologists (ASA) physical status I and II.
  • Underwent shoulder arthroscopic surgery.

Who cannot join

  • Patients who were known to have an allergy to amide type local anesthetics, dexmedetomidine, or fentanyl.
  • Patients who were receiving non-steroidal anti-inflammatory drugs or any chronic drugs for pain management in the past four weeks.
  • Had a history of drug dependency or substance addiction.
  • Body mass index (BMI) of 18.5 or higher.
  • Had a severe spinal deformity.
  • Had an uncontrolled concomitant medical condition.
  • Had a local skin infection at the injection site or spinal metastasis.

Trial locations and contacts

1 site in 1 country.

Egypt1 site
  • Tanta University

    Tanta, El-Gharbia, 31527

Other trials in Egypt

About this study

Official title: Effects of Fentanyl Vs Dexmedetomidine as Adjuvants to Bupivacaine in Erector Spinae Plane Block for Postoperative Analgesia in Patients Undergoing Arthroscopic Shoulder Surgeries

This study aimed to evaluate the effect of fentanyl versus dexmedetomidine as adjuvants to bupivacaine with comparison to bupivacaine alone in ultrasound-guided erector spinae plane block on the quality and duration of pain control in patients undergoing arthroscopic shoulder surgeries.

Read the detailed description

Shoulder arthroscopic surgery is one of the most common surgical procedures performed in daily practice, for many surgical indications as rotator cuff tears, stiffness and instability, this procedure has a well - documented postoperative pain.

The erector spinae plane block (ESPB) is one of the emerging regional techniques for managing postoperative pain. ESPB has been used successfully in many surgeries such as mastectomy, thoracotomies, percutaneous nephrolithotomies, lumbar fusions, hernia repair, cesarean delivery and even in total hip arthroplasty.

Fentanyl as an additive to 0.25% bupivacaine in paravertebral block has been found to reduce the rescue analgesic consumption as well as cumulative pain scores at rest and on movement after breast surgery.

Dexmedetomidine is highly selective than clonidine, specific and potentα2-adrenergic agonist having analgesic, sedative, antihypertensive, and anesthetic sparing effects when used in systemic route.

Being tested
Bupivacaine 0.25%, Bupivacaine 0.25% + Fentanyl 1µg/kg, Bupivacaine 0.25% + dexmedetomidine 1µg/kg

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Bupivacaine 0.25%Drug

    Patients received ultrasound-guided erector spinae plane block (ESPB) using 20 cc of 0.25% bupivacaine at T2.

  • Bupivacaine 0.25% + Fentanyl 1µg/kgDrug

    Patients received ultrasound-guided erector spinae plane block (ESPB) using a total volume of 20 ml (bupivacaine 0.25% + Fentanyl 1µg/kg) at T2.

  • Bupivacaine 0.25% + dexmedetomidine 1µg/kgDrug

    Patients received ultrasound-guided erector spinae plane block (ESPB) using a total volume of 20 ml (bupivacaine 0.25% + dexmedetomidine 1µg/kg) at T2.

Study groups in NCT07836595
Study groupRoleWhat they receive
ESPB with bupivacaine aloneActive comparatorPatients received ultrasound-guided erector spinae plane block (ESPB) using 20 cc of 0.25% bupivacaine at T2.
Receives: Drug: Bupivacaine 0.25%
ESPB with Fentanyl groupExperimentalPatients received ultrasound-guided erector spinae plane block (ESPB) using a total volume of 20 ml (bupivacaine 0.25% + Fentanyl 1µg/kg) at T2.
Receives: Drug: Bupivacaine 0.25% + Fentanyl 1µg/kg
ESPB with Dexmedetomidine groupExperimentalPatients received ultrasound-guided erector spinae plane block (ESPB) using a total volume of 20 ml (bupivacaine 0.25% + dexmedetomidine 1µg/kg) at T2.
Receives: Drug: Bupivacaine 0.25% + dexmedetomidine 1µg/kg

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Degree of pain

    Assessment of postoperative pain was done with numerical rate scale [numerical rate score (NRS); 0=no pain and 10=worst possible pain]. At post-anesthesia care unit (PACU) then 2, 4, 6, 8, 12, and 24 hours postoperative.

    Measured: 24 hours postoperatively

Secondary outcomes (4)
  1. Time of first rescue analgesia

    Time of first rescue analgesia was recorded from the end of surgery till the first dose of morphine adminstrated.

    Measured: 24 hours postoperatively

  2. Intraoperative fentanyl consumption

    Any intraoperative hypertension (mean arterial pressure>20% of baseline) or tachycardia were managed by rescue fentanyl dose 1µg /kg IV when suspected to be caused by intraoperative pain awareness and these cases was recorded.

    Measured: Intraoperatively

  3. Total amount of morphine consumption

    Rescue analgesia in the form of 3 mg IV morphine was given if the numerical rate score (NRS) is ≥ 4 repeated with 10 minutes lockout interval till the (NRS) becomes less than 3.

    Measured: 24 hours postoperatively

  4. Length of hospital stay

    Length of hospital stay was recorded from the admission till the discharge from hospital.

    Measured: Till the discharge from hospital (Up to 2 weeks)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted23 Sep 2026
  2. Study start1 Jan 2024
  3. Primary completion1 Dec 2024
  4. Study completion1 Dec 2024

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Participant
Enrolment
90 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07836595
Sponsor's protocol ID
36265MD170/11/23
Status last verified
Sep 2026
First submitted
17 Sep 2026
Last updated
23 Sep 2026
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: The data will be available upon a reasonable request from the corresponding author after the end of study for one year.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in